Justin A. Green - Concepedia

Author

Justin A. Green

GlaxoSmithKline (United Kingdom)

Also Known As

JUSTIN A. GREEN, Jane C Quinn, Justin A Green, Justin A. Green, Justin A. Green, Prakash Ghimire

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)Medicines for Malaria Venture GlaxoSmithKline (United States)Mahidol University Mahidol Oxford Tropical Medicine Research Unit

About

Justin A. Green is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, malaria, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	744
2	Cell Biology	2	2	108
3	Cellular Physiology	2	2	108
4	Public Health	1	1	14
5	Emergency Medicine	1	1	284

Justin A. Green

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Severe Acute Respiratory Syndrome (SARS) in Singapore: Clinical Features of Index Patient and Initial Contacts Li Yang Hsu, Cheng-Chuan Lee, Justin A. Green, Emerging infectious diseases Emerging Infectious DiseasesRespiratory DiseasesRadiologic FeaturesAcute CareClinical Epidemiology	2003	284
Single-Dose Tafenoquine to Prevent Relapse of <i>Plasmodium vivax</i> Malaria Marcus Lacerda, Alejandro Llanos‐Cuentas, Srivicha Krudsood, New England Journal of Medicine	2019	277
Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study Alejandro Llanos‐Cuentas, Marcus Lacerda, Ronnatrai Rueangweerayut, The Lancet Antiparasitic AgentMedicineMalariaParasite ControlDose-selection Study	2013	242
Tafenoquine versus Primaquine to Prevent Relapse of <i>Plasmodium vivax</i> Malaria Alejandro Llanos‐Cuentas, Marcus Lacerda, Tran Tinh Hien, New England Journal of Medicine	2019	239
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial Meera Madhavan, Adam Ritchie, Jeremy Aboagye, EBioMedicine	2022	138
Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers Ronnatrai Rueangweerayut, Germana Bancone, Emma J. Harrell, American Journal of Tropical Medicine and Hygiene	2017	117
Both CD31<sup>+</sup>and CD31<sup>−</sup>Naive CD4<sup>+</sup>T Cells Are Persistent HIV Type 1–Infected Reservoirs in Individuals Receiving Antiretroviral Therapy Fiona Wightman, Ajantha Solomon, Gabriela Khoury, The Journal of Infectious Diseases	2010	115
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial Pamela L. St. Jean, Zhengyu Xue, Nick Carter, Malaria Journal	2016	99
Synergistic Up-Regulation of Epithelial Cell Matrix Metalloproteinase-9 Secretion in Tuberculosis Paul Elkington, Justin A. Green, Jenny E. Emerson, American Journal of Respiratory Cell and Molecular Biology Inflammatory Lung DiseaseLung InflammationTuberculosis PreventionImmunologyImmune Regulation	2007	79
Dexamethasone, Cerebrospinal Fluid Matrix Metalloproteinase Concentrations and Clinical Outcomes in Tuberculous Meningitis Justin A. Green, Chau Thi Hong Tran, Jeremy Farrar, PLoS ONE	2009	75

Page 1